Fertility warning
This medicine may affect fertility.
Leaflet ETCAMAH 75mg film-coated tablets
- Product code:
- W72144001
- Quantity:
- 28
- Indicated for:
- ER-positive, HER2-negative locally advanced or metastatic breast cancer with an ESR1 mutation detected without progressi
- Route of administration:
- oral
- Substance:
- camizestrant (selective estrogen receptor degrader (SERD))
- ATC
- L02BA05 — Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Anti-estrogens
Precautions:
Driving impairment
This medicine may affect your ability to drive or use machines.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Major drug interactions
This medicine may have important interactions with other medicines.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Do not split / crush / chew
Do not split, crush, or chew this medicine.
Pregnancy warning
Use during pregnancy only on medical advice.
Pediatric warning
Use in children only as recommended in the leaflet or by a doctor.
Cardiac risk / QT prolongation / arrhythmias
This medicine may increase the risk of heart rhythm disturbances.
Teratogenic / fetal risk
This medicine may affect fetal development.
Vision disturbances
This medicine may cause vision disturbances.
General data about ETCAMAH 75mg
- Substance:
- camizestrant
- Date of latest medicines list:
- 01-09-2026
- Product code:
- W72144001
- Concentration:
- 75mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 28
- Product type:
- Original
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.